Bcl2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical responsiveness - reply
1998
Bcl-2 and Bax Proteins in Chronic Lymphocytic Leukaemia
publication
Evidence: moderate
Author Information
Author(s): P Bentley, C Pepper, T Hoy
Primary Institution: Llandough Hospital
Hypothesis
The ratio of Bcl-2 to Bax proteins may determine susceptibility to apoptosis in chronic lymphocytic leukaemia cells.
Conclusion
Bcl-2 and Bax protein levels are significantly different in cells that resist apoptosis compared to those that do not.
Supporting Evidence
- Bcl-2 and Bax protein levels differ significantly in apoptosis-resistant cells.
- The study used Annexin V to measure apoptosis after drug treatment.
Takeaway
This study found that the balance of two proteins, Bcl-2 and Bax, helps decide if cancer cells live or die when treated with drugs.
Methodology
The study used triple-colour analysis to quantify Bcl-2 and Bax proteins in B-lymphocyte populations and measured apoptosis using Annexin V.
Limitations
The study did not differentiate between viable and non-viable cells in the analysis.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website